What does this study of cannabis and cardiovascular disease mean?

Post date: 2024-04-14 12:52:34
Views: 164
A study published in late February by the Journal of the American Heart Association noted as its conclusion, "Cannabis use is associated with adverse cardiovascular outcomes, with heavier use (more days per month) associated with higher odds of adverse outcomes."

As far as I can tell, IANAD, frequency/day of cannabis use doesn't seem to have been taken into account. Intuitively, it would seem that taking a single bong hit vs. smoking multiple joints in a day would be substantially different, but it seems that the study only asked participants how often they used cannabis as in never/sometimes/daily. It also didn't appear to distinguish between methods of consumption, e.g., vape vs. smoke vs. edible.

The results are concerning, certainly, for cannabis users, especially among older users who are the biggest growth group in terms of cannabis use, I believe, and I wondered if any MeFites with greater knowledge of the topic could note the real-world significance and/or flaws in this study. Thanks.
Please click Here to read the full story.
 
Other Top and Latest Questions:
Disney beats Wall Street expectations propelled by theme parks and streaming
Elon Musk has lauded the 'social media for AI agents' platform Moltbook as a bold step for AI. Others are skeptical
Disney supercharged its parks. The booming division still has room to run
Nvidia shares are down after a report that its OpenAI investment stalled. Here's what's happening
Women say caregiving and child care costs are the No. 1 reason they quit the workforce last year, according to new data
What Trump's choice of Kevin Warsh for Fed chair may mean for consumers
How the EV pullback is affecting factories and jobs in the South
How to show question title before question meta in question list. (Mayropro theme)
China ramps up threats over Panama Canal ruling that handed Trump a major victory
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar